104 related articles for article (PubMed ID: 9037370)
1. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.
Younes A; Cabanillas F; McLaughlin PW; Hagemeister FB; Farber C; Sarris A; Pate O; Myers J; Portlock C
Ann Oncol; 1996 Dec; 7(10):1083-5. PubMed ID: 9037370
[TBL] [Abstract][Full Text] [Related]
2. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes A; Sarris A; Melnyk A; Romaguera J; McLaughlin P; Swan F; Rodriguez MA; Hagemeister F; Moore D; North L
J Clin Oncol; 1995 Mar; 13(3):583-7. PubMed ID: 7884419
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
Younes A; Ayoub JP; Sarris A; Hagemeister F; North L; Pate O; McLaughlin P; Rodriguez MA; Romaguera J; Kurzrock R; Preti A; Bachier C; Smith T; Cabanillas F
Br J Haematol; 1997 Feb; 96(2):328-32. PubMed ID: 9029021
[TBL] [Abstract][Full Text] [Related]
4. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Younes A; Ayoub JP; Hagemeister FB; McLaughlin P; Sarris A; Rodriguez MA; Swan F; Romaguera JE; Martin J; Cabanillas F
J Clin Oncol; 1996 Feb; 14(2):543-8. PubMed ID: 8636769
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Sarris AH; Younes A; McLaughlin P; Moore D; Hagemeister F; Swan F; Rodriguez MA; Romaguera J; North L; Mansfield P; Callendar D; Mesina O; Cabanillas F
J Clin Oncol; 1996 Jan; 14(1):233-9. PubMed ID: 8558203
[TBL] [Abstract][Full Text] [Related]
8. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.
Goss P; Stewart AK; Couture F; Klasa R; Glück S; Kaizer L; Burkes R; Charpentier D; Palmer M; Tye L; Dulude H
Leuk Lymphoma; 1999 Jul; 34(3-4):295-304. PubMed ID: 10439366
[TBL] [Abstract][Full Text] [Related]
9. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
12. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease.
Smith MR; Khanuja PS; al-Katib A; Bishop CR; Andersen J; Hussein ME; Karanes C
Cancer; 1994 Feb; 73(4):1264-9. PubMed ID: 7508818
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-based treatment of lymphoma.
Younes A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
